Quinapril/HCTZ 20mg/12.5mg – Aurobindo

The FDA announced a consumer-level recall of two lots of Aurobindo's quinapril/hydrochlorothiazide (HCTZ) 20 mg/12.5 mg tablets due to the presence of nitrosamine drug substance-related impurity (NDSRI), N-Nitroso-Quinapril, above the proposed interim limit.

Product	Quinapril/HCTZ Tablets USP, 20mg/12.5mg, 90's HDPE bottle
Lot number	QE2021005-A QE2021010-A
Expiry	01/2023
Manufacturer	Aurobindo
Recall identification date	10/25/2022
Affected NDC	65862-0162-90

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.

Consumers with medical questions regarding this recall or to report an adverse event can contact Aurobindo Pharma USA, Inc. at:

- 1-866-850-2876 (Option 2), 24 hours per day, 7 days per week; or
- pvg@aurobindousa.com